Anticipated Spike in Deal Activity in 2021 Makes Customized R&W Insurance Critical, Finds Lowenstein Sandler

NEW YORK–(BUSINESS WIRE)–Encouraging news about COVID-19 vaccination trials and the impending resolution of the long election process bode well for deal activity in 2021, according to M&A and insurance recovery lawyers from Lowenstein Sandler. With an anticipated increase in financial transactions, competition among insurers is also expected to heat up, making this an ideal time … [Read more…]

ImmunityBio Simulates SARS-CoV-2 Spike Protein Binding Using Molecular Dynamics

Detailed computer modeling, completed in partnership with Microsoft, explains virulence of COVID-19 and provides key information that may lead to a better understanding of the multiple mutations currently occurring to the “spike” protein as the virus evolves Computer-based molecular dynamics simulation allows highly detailed visualization of free (unbound) spike receptor binding domain (S RBD) and … [Read more…]

Vicks® Donates $1 million for COVID-19 Health Care Relief

Humanitarian Aid Organization, Direct Relief, will use the funds to deliver protective gear and essential medical aid to health care organizations CINCINNATI–(BUSINESS WIRE)–In response to the novel coronavirus (COVID-19) pandemic, the Vicks® family of cold and flu brands – NyQuil™, DayQuil™ and VapoRub™ – will donate $1 million to Direct Relief, one of the world’s … [Read more…]

Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

– Data show that combination of two antibodies in Immunome’s cocktail successfully neutralized the Omicron variant in vivo in hamsters – – IMM20253 antibody also retained activity against BA.2 subvariant in pseudovirus testing in vitro, with additional testing underway – EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B … [Read more…]

Blue Spark Technologies Raises $40 Million in Growth Funding Led by Ghost Tree Partners to Advance AI-Based Remote Patient Monitoring

Funding will accelerate company’s growth and widespread adoption of continuous wearable remote patient monitoring solutions CLEVELAND–(BUSINESS WIRE)–Blue Spark Technologies, Inc., a leader in wearable remote patient monitoring solutions, today announced that it has raised a $40 million intellectual property-based debt solution to fund growth led by GT Investment Partners (“Ghost Tree Partners”) with support from … [Read more…]

Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated preclinical results providing further evidence for Bicycles as a potential novel antiviral modality against SARS-CoV-2. The results will be presented in an oral presentation … [Read more…]

United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation

In subjects with PAH, transition from Tyvaso® to Tyvaso DPI™ demonstrated safety and tolerability with significant improvements in six-minute walk distance, device preference and satisfaction, and patient reported outcomes Tyvaso DPI safety confirmed through 51 weeks of optional extension phase data with no study drug-related serious adverse events FDA action on the New Drug Application … [Read more…]

Immunome Reports Fourth Quarter and Full Year 2021 Financial Results

– Immunome Receives Safe-to-Proceed Notification from U.S. FDA for IMM-BCP-01 Investigational New Drug Application – – Immunome Continues to Progress IMM-BCP-01 Towards Phase 1b Clinical Trial – – Ongoing Progress on Oncology Pipeline, Including Lead Program Targeting IL-38, a Novel Innate Immunome Checkpoint – EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes … [Read more…]

FDA Lifts Clinical Hold on Immunome’s IMM-BCP-01 IND Application for the Treatment of COVID-19

EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of … [Read more…]

Celltrion Submits Investigational New Drug (IND) Application to Initiate a Global Phase III Clinical Trial Evaluating an Inhaled COVID-19 Antibody Cocktail Therapy

Celltrion submitted an IND application for a global Phase III clinical trial of inhaled antibody cocktail therapy with CT-P59 and CT-P63; the company expects to enrol 2,200 patients with mild-to-moderate symptoms of COVID-19 The inhaled COVID-19 antibody cocktail therapy and CT-P63 maintained strong neutralising ability against the Omicron variant (B.1.1.529) The inhaled COVID-19 antibody cocktail … [Read more…]